Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAMION Lung-2 first-line zongertinib vs standard of care in HER2-mutant NSCLC
2023-504308-27-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zongertinib monotherapy with Platinum-pemetrexed plus pembrolizumab standard of care (2 arms). Primary endpoint: Progression-free survival (PFS) by blinded central independent review (RECIST 1.1). Planned start Jun 2024; status: authorised.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504308-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504308-27-00.